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Endothelial microparticles are effectors of endothelial damage; however mechanisms involved are unclear. We examined the effects
of eMPs on cultured endothelial cells (ECs) and isolated vessels and investigated the role of eMP-derived reactive oxygen species
(ROS) and redox signaling in these processes. eMPs were isolated from EC media and their ability to directly produce ROS was
assessed by lucigenin and liquid chromatography. Nicotinamide adenine dinucleotide phosphate oxidase (Nox) subunits were
probed by Western blot. ECs were treated with eMPs and effects on kinase signaling, superoxide anion (O
2
∙−) generation, and
nitric oxide (NO) production were examined. Acetylcholine-mediated vasorelaxation was assessed by myography in eMP-treated
mesenteric arteries. eMPs contained Nox1, Nox2, Nox4, p47phox, p67phox, and p22phox and they produced ROS which was inhibited
by the Nox inhibitor, apocynin. eMPs increased phosphorylation of ERK1/2 and Src, increased O
2
∙− production, and decreased
A23187-induced NO production in ECs. Pretreatment of eMPs with apocynin diminished eMP-mediated effects on ROS and NO
production but had no effect on eMP-mediated kinase activation or impairment in vasorelaxation. Our findings identify a novel
mechanismwhereby eMP-derived ROS contributes toMP bioactivity.These interactionsmay be important in conditions associated
with vascular injury and increased eMP formation.
1. Introduction
The endothelium plays a critical role in the regulation of
blood flow, cellular trafficking, coagulation, and inflamma-
tion [1, 2]. Normal endothelial function requires a dynamic,
controlled communication system between endothelial cells
(ECs) and vascular smooth muscle cells, fibroblasts, and
immune cells that employ electrical signals, cell-cell/cell-
matrix contacts, cytokines/proteins, small molecules, and
gases such as nitric oxide [2–4]. In addition, intercellular
communication may involve the release of extracellular vesi-
cles, which can function as intercellular carriers of ligands,
enzymes, RNA, and miRNA [5–7]. Vascular cells have been
shown to release vesicles of differing origins that contribute to
many (patho)physiological processes including angiogenesis,
coagulation, inflammation, and fibrosis [8].
Microparticles (MPs, sometimes referred to asmicrovesi-
cles or ectosomes) are 100–1000 nm anuclear vesicles formed
following cytoskeletal and membrane reorganization and
release from cells into the extracellular milieu [7, 8]. In
biological samples, alterations in MP levels may be indicative
of underlying pathology, correlate with measures of vascular
dysfunction, and predict risk of adverse cardiovascular events
[8–10]. MPs are also potent autocrine/paracrine signals for
various cellular responses [11]. For example, endothelial
MPs promote cell senescence, oxidative stress, coagulation,
inflammation, and apoptosis [8, 12–15]. Amongst the many
responses initiated by endothelialMPs in ECs is the induction
of reactive oxygen species (ROS) production. Initial studies
by Brodsky et al. showed that endothelial MPs induce O
2
∙−
production in cultured rat renal microvascular ECs and in ex
vivo aortic rings [16]. A follow-up study implicated ROS in
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Table 1: List of antibodies used.
Antibody Species Supplier Catalog number Dilution factor
Nox1 Goat Santa Cruz Biotechnology sc-5821 1 : 2000
Nox2/gp91phox Goat Santa Cruz Biotechnology sc-5827 1 : 1000
Nox4 Goat Santa Cruz Biotechnology sc-21860 1 : 1000
p22phox Rabbit Santa Cruz Biotechnology sc-20781 1 : 1000
p47phox Goat Santa Cruz Biotechnology sc-7660 1 : 1000
p67phox Rabbit Abcam ab109366 1 : 1000
Phospho-ERK1/2 (Thr202/Tyr204) Rabbit Cell Signaling Technology 9101S 1 : 2000
Total ERK1/2 Rabbit Cell Signaling Technology 9102S 1 : 2000
Phospho-Src (Tyr416) Rabbit Cell Signaling Technology 2101S 1 : 2000
Total Src Rabbit Cell Signaling Technology 2108 1 : 2000
Phospho-eNOS (Ser1177) Rabbit Cell Signaling Technology 9571 1 : 1000
Phospho-eNOS (Thr495) Rabbit Cell Signaling Technology 9574 1 : 1000
Total eNOS Rabbit Cell Signaling Technology 9572 1 : 2000
Phospho-AKT (Ser473) Rabbit Cell Signaling Technology 9271 1 : 2000
Total AKT Rabbit Cell Signaling Technology 9272 1 : 2000
Donkey anti-goat HRP Donkey Santa Cruz Biotechnology sc-2033 1 : 2000
Goat anti-rabbit HRP Goat Santa Cruz Biotechnology sc-2030 1 : 2000
Goat anti-mouse Goat Santa Cruz Biotechnology sc-2031 1 : 2000
the antiangiogenic effects of endothelial MPs [17]. Similarly
ROS production has been shown in human umbilical vein
ECs exposed to endothelial MPs [18–20]. We have observed
that exogenous endothelial MPs induce ROS production in
ECs through both mitochondrial and nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases [12, 13]. More
controversially, it has been suggested that endothelial MPs
may directly produce ROS. Brodsky et al. examined de novo
ROS production by endothelial MPs by DHE staining and
observed p22phox within endothelial MPs [16]. NADPH oxi-
dase activity has also been reported in aortic endothelial MPs
and may be influenced by glucose exposure [21]. However,
to date, there has been no direct evidence that MPs possess
the complete machinery necessary to produce ROS, nor has
the role of de novo ROS production on MP-mediated EC
responses been evaluated.
The purpose of this study was to evaluate whether
endothelial MPs produce ROS and to evaluate the potential
regulatory role of MP-derived ROS on EC signaling and
vascular function.
2. Materials and Methods
2.1. Reagents. NaCl, D-glucose, KH
2
PO
4
, NaF, dihydroethid-
ium (DHE, stock 10mM in DMSO), Tris-base, Dulbecco’s
Modified Eagle Media (DMEM), fetal calf serum (FCS),
penicillin/streptomycin, 1x minimal essential amino acids,
and 4-amino-5-methylamino-2󸀠,7󸀠-difluorofluorescein diac-
etate (DAF, stock 10mM in DMSO) were all purchased
fromThermo Fisher Scientific (Waltham,MA, USA). Acetyl-
choline, phenylephrine, leupeptin, aprotinin, sodium ortho-
vanadate, pepstatin, phenylmethylsulfonyl fluoride (PMSF),
NaHCO
3
, ethylene glycol tetraacetic acid (EGTA), A23187
(calcium ionophore, stock 10mM in DMSO), sodium deoxy-
cholate, NP40, lucigenin, diethylenetriaminepentaacetic acid
(DTPA), apocynin, and endothelial cell growth supplement
were all purchased fromSigma-Aldrich (St. Louis,MO,USA).
KCl, CaCl
2
, MgSO
4
, and ethylene-diaminetetraacetic acid
(EDTA) were all purchased from EMD Millipore (Billerica,
MA, USA). Sodium dodecyl sulfate (SDS) and NADPH were
purchased fromVWR (Radnor, PA, USA). Alexa-647-labeled
Annexin V were purchased from BioLegend (San Diego,
CA, USA). Heparin was purchased through Leo Pharma
(Thornhill, ON, Canada). A complete list of all antibodies
used and their sources is provided in Table 1.
2.2. Animals. The study was approved by the Animal Ethics
Committee of the University of Ottawa and performed
according to the recommendations of the Canadian Council
for Animal Care.
2.3. Cell Culture. ECs were isolated from aortas of C57BL6/J
mice as we previously described [13, 22]. Cells were cultured
on attachment factor-coated polystyrene dishes in DMEM
containing 10% FCS, 50mg/L of EC growth supplement,
10U/mL heparin, 100U/mL penicillin/streptomycin, and 1x
minimal essential amino acids and placed in a humidified
incubator at 37∘C and 5% CO
2
.
2.4. Endothelial Microparticle Isolation and Quantification.
Endothelial MPs were isolated from media collected from
EC cultures using a modification of our previously described
methods [13, 23]. Samples were centrifuged at 2500 g for 10
minutes at 4∘C to obtain cell-free media. MPs were then
pelleted from cell-free media by centrifugation at 20000×g
for 20 minutes at 4∘C. Endothelial MPs were confirmed
as such and quantified by flow cytometry using an Alexa-
647-labeled Annexin V (0.5𝜇g/mL final concentration in
Annexin V binding buffer) to identify events as MPs. As a
negative control, a subpopulation of MPs were resuspended
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in Annexin V binding buffer lacking calcium, which is
necessary for Annexin V binding to phosphatidylserine. MPs
were centrifuged and resuspended in assay-specific buffers
(indicated below) or 1x phosphate buffered saline for cell
treatment studies. A final concentration of 105MPs/mL,
previously identified to exert effects on cultured ECs, was
used for treatments [12, 13].
2.5. Measurement of ROS Production. ROS production
was measured by lucigenin chemiluminescence and by
DHE/HPLC in MPs and ECs. For chemiluminescence, MPs
were isolated from 100mL of media and lysed in a buffer
containing (20mM of KH
2
PO
4
, 1 mM of EGTA, 1 𝜇g/mL
of aprotinin, 1 𝜇g/mL of leupeptin, 1 𝜇g/mL of pepstatin,
and 1mM of PMSF). Following lysis, 50𝜇L of sample was
added to 175 𝜇L of assay buffer (50mM of KH
2
PO
4
, 1 mM of
EGTA, and 150mM of sucrose) and 5 𝜇M lucigenin. NADPH
(1mM) was added to the suspension (300 𝜇L) containing
lucigenin. Luminescence was measured on a Berthold Orion
II luminometer (Berthold Detection Systems, Pforzheim,
Germany) in 1 s readings over a total of 30 cycles before and
after stimulationwithNADPH.Abuffer blankwas subtracted
from each reading. As a negative control, the high-speed
supernatant obtained during MP isolation was also assessed.
The results are expressed as counts per mg of protein.
For HPLC studies, MPs were isolated from 100mL of
media and incubated in DHE (50 𝜇M final concentration in
a buffer containing 1.3mM CaCl
2
, 0.8mM MgSO
4
, 5.4mM
KCl, 0.4mM KH
2
PO
4
, 4.3mM NaHCO
3
, 137mM NaCl,
0.3mM Na
2
HPO
4
, 5.6mM glucose, and 100 𝜇M DTPA, pH
7.4) for 30 minutes in the presence and absence of the
Nox inhibitor, apocynin (10 𝜇M). DHE oxidation was then
assessed by HPLC as described previously [13]. As a negative
control, the high-speed supernatant obtained during MP
isolation was also assessed.
2.6. Western Blot Analysis. Western blotting was used
to examine the presence of NADPH oxidase subunits
in endothelial MPs and to assess intracellular signal-
ing responses in cultured ECs. Membranes were probed
with anti-phosphorylated extracellular signal-related kinase
(ERK1/2), anti-total ERK1/2, anti-phosphorylated Src, anti-
total Src, anti-phosphorylated Akt, anti-total Akt, anti-
phosphorylated (ser1177) eNOS, anti-phosphorylated (thr-
495) eNOS, anti-total eNOS, anti-Nox1, anti-Nox2, anti-
Nox4, anti-p22phox, anti-p47phox, and anti-p67phox. Mem-
branes were then washed in TBS-T and incubated with horse-
radish peroxidase- (HRP-) conjugated secondary antibodies
in milk for 1 h. Membranes were probed for immunore-
activity by chemiluminescence. Quantification of blots was
performed by densitometry (Image J, National Institute of
Health, Baltimore, MD, USA).
2.7. Nitric Oxide Production. Measurement of EC nitric oxide
production was performed using a fluorescence-based assay
with live cell imaging [24–26]. Cells were loaded with the
fluorescent NO-sensitive dye DAF (0.5 𝜇M final concen-
tration) and incubated at 37∘C for 30 minutes. Coverslips
containing DAF-loaded cells were placed in a tempera-
ture regulated (37∘C) chamber mounted on the stage of
an inverted microscope in Krebs-Ringer phosphate (KRP)
buffer (120mM NaCl, 4.8mM KCl, 0.54mM CaCl
2
, 1.2mM
MgSO
4
, 11mM glucose, and 15.9mM sodium phosphate, pH
7.2). Changes in cellular DAF fluorescence intensities were
simultaneously acquired for multiple cells (defined regions
of interest) using a Stallion Digital Hi-Speed Multi-Channel
Imaging System (Zeiss, Germany)with 495 nmexcitation and
515 nm emission. Changes in NO induced by exposure to the
calcium ionophore A23187 (1 𝜇M final concentration) were
measured in relation to baseline fluorescence as described
elsewhere [24–26]. Unstimulated and A23187 stimulated NO
production was observed as the difference between the
NO content measured in the presence (total) and absence
(basal) of treatment and expressed as percentage of the basal
considered as 100%.
2.8.Myography. Second-order branches ofmousemesenteric
artery were isolated and cleaned of adhering fat and con-
nective tissue. Vessels segments (1.5–2mm) were mounted
on a wire myograph and equilibrated in a physiological
saline solution (in mM; 130 NaCl, 14.9 NaHCO
3
, 4.7 KCl,
1.18 KH
2
PO
4
, 1.17 MgSO
4
, 1.6 CaCl
2
, 0.026 EDTA, and 5.5
glucose, pH 7.4, 37∘C) which was bubbled continuously with
95% O
2
and 5% CO
2
. Endothelium-dependent relaxation
was assessed in the presence and absence of endothelial
MPs (105MPs/mL) as previously described [27]. Vessels
were preincubated with MPs for 30 minutes. Endothelium-
dependent relaxation was then examined by measuring
dilatory responses to acetylcholine (1 nM–10 𝜇M) in vessels
precontracted with phenylephrine at a concentration which
was found to cause approximately 80%maximal contraction.
2.9. Statistical Analysis. Results are expressed as mean ±
SEM and were analyzed using a one-way ANOVA with
Bonferroni’s posttest using Prism 5.0 (GraphPad Software,
Inc., La Jolla, CA, USA). 𝑃 < 0.05was considered statistically
significant.
3. Results
3.1. MPs Possess NADPH Oxidases and Generate ROS. To
determine whether MPs contain ROS-generating enzymes,
we examined the presence of NADPH oxidase subunits in
endothelial MPs. Both cultured ECs and endothelial MPs
were found to contain Nox1, Nox2, Nox4, p22phox, p47phox,
and p67phox (Figure 1(a)). Compared with ECs, endothelial
MPs were enriched in Nox4 and p22phox, while Nox1 and
p67phox were found at lower levels. No NADPH oxidase sub-
units were detectable in the high-speed supernatant obtained
during MP isolation.
As shown in Figure 1(b) lucigenin chemiluminescence
revealed that endothelial MPs produced O
2
∙−, a process
that was attenuated by treatment with the NADPH oxidase
inhibitor apocynin (5𝜇M). Similarly, O
2
∙− production was
detectable by DHE/HPLC and was inhibited by apocynin
(Figure 1(c)).
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Figure 1: Nox machinery and ROS production in endothelial cells (EC), supernatant (SN), and endothelial microparticles (MP). (a)
Expression of Nox1, Nox2, Nox4, p22phox, p47phox, and p67phox was measured by Western blot analysis in EC, SN, and MP. MPs were isolated
from the media of mouse aortic ECs. Blots are representative of at least four independent experiments. (b, c) ROS production by endothelial
MPs as determined by lucigenin (b) and DHE/HPLC (c) in the presence and absence of the NADPH oxidase inhibitor apocynin (10 𝜇M).
∗
𝑃 < 0.01, MP versus SN, +𝑃 < 0.01MP + apocynin versus MP, 𝑛 = 3–5.
3.2. Effects of Endothelial MPs on Intracellular Signaling in
Cultured ECs. In order to assess EC signaling following
endothelial MP exposure, ECs were treated with endothelial
MPs for 0–24 hours and phosphorylation of ERK1/2, Src, p38,
and Akt kinases was measured by Western blot analysis. As
shown in Figure 2. MPs increased ERK1/2 phosphorylation
at 30 minutes and 1 hour while Src was increased at 4 hours.
Conversely, Akt and p38 phosphorylation were unchanged
over 24 hours (not shown).
3.3. Effects of Endothelial MPs on eNOS Activation and
NO Production in Cultured ECs. Stimulation of ECs with
endothelial MPs was associated with an impairment in
eNOS activation and NO production. Following exposure
to endothelial MPs, phosphorylation of eNOS (serine 1177,
associated with enzyme activation) was decreased suggesting
impaired NO production (Figure 3(a)), while phosphoryla-
tion at threonine 495 (associated with enzyme inhibition)
was unchanged (Figure 3(b)). Consistent with a decrease in
eNOS activity, we observed a decrease in calcium-dependent
NO production assessed by DAF-FM. Exposure to A23187
(10 𝜇M) was associated with a 5-6-fold increase in fluores-
cence, indicative of NO production, and consistent with
previous reports [28] (Figure 4). Preincubation of ECs with
endothelial MPs significantly impaired A23187-induced NO
production in ECs.
Oxidative Medicine and Cellular Longevity 5
P-ERK
T-ERK
Time (hours) 0.25 0.5 1 2 4 8 240
0.25 0.5 1 2 4 8 240
Time (hours)
0
1
2
3
4
P-
ER
K/
T-
ER
K
∗
∗
(a)
P-Src
T-Src
Time (hours) 0.25 0.5 1 2 4 8 240
0.25 0.5 1 2 4 8 240
Time (hours)
0.0
0.5
1.0
1.5
2.0
2.5
P-
Sr
c/
T-
Sr
c
∗
(b)
Figure 2: Effects of endothelial MPs on kinase signaling in cultured mouse aortic ECs. ECs were exposed to endothelial MPs (105/mL) and
phosphorylation of ERK1/2 (a) and Src (b) was examined by Western blot analysis. ∗𝑃 < 0.05 versus no treatment (0 hours), 𝑛 = 4–6.
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Figure 3: Effects of endothelial MPs on phosphorylation of eNOS in cultured mouse aortic ECs. ECs were exposed to endothelial MPs
(105/mL) and phosphorylation of eNOS at activation site, residue serine 1177 (a), and inhibitory site, residue threonine 495 (b), was examined
by Western blot analysis. ∗𝑃 < 0.05 versus no treatment (0 hours), 𝑛 = 4–6.
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Figure 4: Effects of endothelial MPs on NO production (a, b) and ROS production (c) in cultured mouse aortic ECs. ECs were exposed to
endothelial MPs (105/mL, 4 hours) or endothelial MPs pretreated with the NADPH oxidase inhibitor apocynin (Apo MPs, 105/mL, 4 hours).
(a, b) NO production was measured in A23187 (10𝜇M) stimulated ECs using diaminofluorescein diacetate and fluorescence microscopy.
MP treatment impaired A23187 stimulated NO production and this process was partially attenuated by NADPH oxidase inhibition in
microparticles. ∗𝑃 < 0.05 versus unstimulated cells, †𝑃 < 0.05 versus stimulated control group, 𝑛 = 11-12. (c) EC ROS production was
assessed by DHE-HPLC. ∗𝑃 < 0.05 versus unstimulated cells, †𝑃 < 0.05 versus stimulated control group, 𝑛 = 3-4.
3.4. Effects of MP-Derived ROS on Endothelial Cell Signaling.
To determine if de novo production of ROS plays a role in
the biological actions of endothelial MPs endothelial MPs
were pretreated with apocynin and administered to cultured
ECs. Apocynin pretreatment partially attenuated endothelial
MP-mediated inhibition of NO production (Figures 4(a)
and 4(b)) and MP-mediated induction of ROS production
(Figure 4(c)) but had no effect on endothelial MP-mediated
ERK1/2 or Src phosphorylation (Figure 5).
3.5. Effects of Endothelial MPs on Endothelium-Dependent
Vasorelaxation in Isolated Mesenteric Arteries. Finally, to
determine whether endothelial MPs influence endothelium-
dependent vasorelaxation we assessed endothelium-
dependent relaxation induced by acetylcholine (ACh) in
phenylephrine precontracted arteries (Figure 6). As shown
in Figure 6, endothelium-dependent relaxation induced by
ACh was impaired in mesenteric arteries pretreated with
endothelial MPs. Preincubation of endothelial MPs with
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Figure 5: Effects of inhibition of NADPH oxidase activity on MP-mediated kinase signaling responses in mouse aortic ECs. Inhibition of
NADPH oxidase with apocynin inhibition had no effect on endothelial MP-mediated activation of ERK1/2 (a) or Src (b). ∗𝑃 < 0.05 versus
control, 𝑛 = 4.
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Figure 6: Effect of endothelial MPs on endothelium-dependent vasorelaxation in isolated mesenteric arteries. (a) Concentration-response
curve to acetylcholine in untreated control vessels, those incubated with endothelial MPs (105/mL, 30 minutes) or those incubated with
endothelial MPs pretreated with the NADPH oxidase inhibitor apocynin (Apo MPs, 105/mL, 30 minutes). ∗𝑃 < 0.05 versus control vessels at
corresponding dose, 𝑛 = 3–8. (b) Sensitivity to acetylcholine (expressed as pD2 [− log EC50]). ∗𝑃 < 0.05 versus control, 𝑛 = 3–8.
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apocynin did not alter MP-mediated effects on mesenteric
artery relaxation.
4. Discussion
Endothelial MPs influence EC function through redox-
sensitive processes; however the molecular mechanisms
underlying this are unclear. In the present study we show
that endothelial MPs contain NADPH oxidase subunits,
produce ROS in an NADPH oxidase-dependent fashion, and
induce downstream effects on EC signaling. At the functional
level, endothelial MPs influence vascular tone by inhibiting
endothelium-dependent vasorelaxation. EC regulation by
MPs occurs in a paracrine manner, where MP-derived ROS
downregulates eNOS activity and stimulates ROS produc-
tion, without influencing MAP kinases or Src. Our findings
highlight novel signaling mechanisms through de novo ROS
production by MPs and indicate that MP-derived ROS
differentially regulate redox and kinase signaling in ECs. Such
processes may influence endothelial function in conditions
associated with increased endothelial MP production, such
as in atherosclerosis, hypertension, or diabetes.
Microparticles typically possess membrane and cytoplas-
mic proteins/content of the parent cell from which they are
derived. Here we show, similar to what has been demon-
strated in ECs, that MPs express Nox isoforms and NADPH
oxidase subunits, which are functionally active since ROS
is produced in an apocynin-inhibitable manner. H
2
O
2
, a
direct or indirect product of NADPH oxidase activation, is
cell membrane-permeable and, as such, MP-derived ROS
may influence ECs without direct physical contact. This
observation may be of particular relevance in the in vivo
setting where physical interaction between circulating MPs
and the endothelium may be limited due to the presence of a
glycocalyx, flow, or possibly atherosclerotic lesions. MPs also
influence ECs through direct communication.We and others
have reported that surface interactions involving ligand-
mediated receptor activation contribute to endothelial MP
bioactivity [13, 15, 29] while uptake of endothelial MPs has
been implicated in processes associated with coagulation and
inflammation [18, 30].
Although there is increasing interest in the role of
endothelial MPs as redox biovectors of endothelial dysfunc-
tion and vascular inflammation, there is a paucity of informa-
tion as to whether MPs themselves can generate ROS. Brod-
sky et al. reported that ROS are produced in isolatedMPs and
identified the presence of p22phox [16]. However that study
failed to identify the Nox machinery responsible for ROS
production and in fact did not demonstrate Nox-dependence
of the observed ROS production. Similarly, Jansen and
colleagues reported ROS production by endothelial MPs and
suggested that this may be dependent upon NADPH oxidase
but the enzymatic machinery required for ROS production
was again unclear [21]. Others have reported the presence of
certain Nox machinery (p22phox, Nox2) in platelet-derived
exosomes [31]. Our data show that endothelial MPs possess
Nox1, Nox2, Nox4, p22phox, p47phox, and p67phox. Accord-
ingly, ROS production in MPs may be mediated through
multiple Nox isoforms. Of note is the observation that Nox1
and p67phox were present at lower levels than seen in ECs
while Nox4 and p22phox were enriched in MPs.
Wemeasured ROS production by twomethods, lucigenin
chemiluminescence and DHE/HPLC. Lucigenin assesses
ROS production in lysed samples supplemented with
NADPH such that endogenous sources of electrons are not
required. On the other hand, DHE/HPLC methodology
requires an intact system with an endogenous source
of electrons for enzymatic activity. Thus it appears that
endothelial MPs contain at least some source of NADPH that
fuels ROS production. This observation is consistent with
that reported by others where ROS was produced in MPs in
the absence of NADPH supplementation [16, 21]. The source
of electrons in endothelial MPs is presently unclear since
MPs have not been shown to contain NADPH-generating
enzymes. One possibility may be that NADPH in MPs is a
residual component that derives from the cytosolic material
of parent ECs released during MP formation.
Using apocynin, a pharmacological NADPH oxidase
inhibitor, we showed that endothelial MPs require de novo
ROS production for inhibition of eNOS-derived NO pro-
duction and for endothelial MP-mediated induction of ROS
production in ECs. While endothelial MPs reduced eNOS
phosphorylation and NO production, we did not see any
alterations in Akt signaling and mechanisms responsible for
impairedNOproduction are unclear at this time. It is possible
that endothelial MPs interfere with intracellular calcium
handling or reduce eNOS cofactors. Alternatively, endothelial
MPs may influence levels of protein phosphatase 2a (PP2A)
which dephosphorylates eNOS at serine 1177 [32]. A recent
proteomic analysis found PP2Apresent in human endothelial
cell-derivedMPs and it is conceivable that eMPsmay transfer
bioactive PP2A to target cells but this has not been shown
experimentally.
Endothelial MP-mediated effects on intracellular ERK1/2
and Src as well as effects on vasorelaxation were not altered
in apocynin-treated MPs suggesting that these processes are
not influenced by MP-derived ROS. Such findings highlight
the pleiotropic nature of MPs with both ROS-dependent
and ROS-independent pathways contributing to endothelial
MP-mediated signaling. Accordingly it is our belief that
the observed ROS effects are not generalized phenomena
but highly regulated processes. Exact mechanisms whereby
MPs mediate their ROS-independent effects are unclear.
One possibility is the activation of cell surface receptors by
endothelial MPs. For example, we have previously reported
that inhibition of epidermal growth factor receptor (an
upstream activator of ERK1/2 and Src) blocks endothelial
MP-mediated responses in culturedmouse aortic endothelial
cells [13]. EndothelialMPsmay conceivably activate other cell
surface receptors; however this remains an area in need of
investigation.
In summary, we demonstrate that endothelial MPs pro-
duce ROS through Nox-dependent processes, which con-
tribute to endothelial O
2
− generation and downregulation
of NO generation without effect on ERK1/2 and Src acti-
vation or on MP-mediated impairment of vasorelaxation.
Our findings indicate that MPs differentially influence EC
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function through redox-sensitive and insensitive processes.
Modulation of vascular function by MPs appears to be
NADPH oxidase/ROS-independent and may involve ERK1/2
and Src or other mechanisms. Cross talk between MPs and
ECs may be important in conditions associated with vascular
injury and increased endothelial MP formation.
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